Prabhu Roshan S, Miller Katherine R, Asher Anthony L, Heinzerling John H, Moeller Benjamin J, Lankford Scott P, McCammon Robert J, Fasola Carolina E, Patel Kirtesh R, Press Robert H, Sumrall Ashley L, Ward Matthew C, Burri Stuart H
1Levine Cancer Institute, Atrium Health.
2Southeast Radiation Oncology Group; and.
J Neurosurg. 2018 Dec 14;131(5):1387-1394. doi: 10.3171/2018.7.JNS181293. Print 2019 Nov 1.
Preoperative stereotactic radiosurgery (SRS) is a feasible alternative to postoperative SRS and may lower the risk of radiation necrosis (RN) and leptomeningeal disease (LMD) recurrence. The study goal was to report the efficacy and toxicity of preoperative SRS in an expanded patient cohort with longer follow-up period relative to prior reports.
The records for patients with brain metastases treated with preoperative SRS and planned resection were reviewed. Patients with classically radiosensitive tumors, planned adjuvant whole brain radiotherapy, or no cranial imaging at least 1 month after surgery were excluded. Preoperative SRS dose was based on lesion size and was reduced approximately 10-20% from standard dosing. Surgery generally followed within 48 hours.
The study cohort consisted of 117 patients with 125 lesions treated with single-fraction preoperative SRS and planned resection. Of the 117 patients, 24 patients were enrolled in an initial prospective trial; the remaining 93 cases were consecutively treated patients who were retrospectively reviewed. Most patients had a single brain metastasis (70.1%); 42.7% had non-small cell lung cancer, 18.8% had breast cancer, 15.4% had melanoma, and 11.1% had renal cell carcinoma. Gross total resection was performed in 95.2% of lesions. The median time from SRS to surgery was 2 days, the median SRS dose was 15 Gy, and the median gross tumor volume was 8.3 cm3. Event cumulative incidence at 2 years was as follows: cavity local recurrence (LR), 25.1%; distant brain failure, 60.2%; LMD, 4.3%; and symptomatic RN, 4.8%. The median overall survival (OS) and 2-year OS rate were 17.2 months and 36.7%, respectively. Subtotal resection (STR, n = 6) was significantly associated with increased risk of cavity LR (hazard ratio [HR] 6.67, p = 0.008) and worsened OS (HR 2.63, p = 0.05) in multivariable analyses.
This expanded and updated analysis confirms that single-fraction preoperative SRS confers excellent cavity local control with very low risk of RN or LMD. Preoperative SRS has several potential advantages compared to postoperative SRS, including reduced risk of RN due to smaller irradiated volume without need for cavity margin expansion and reduced risk of LMD due to sterilization of tumor cells prior to spillage at the time of surgery. Subtotal resection, though infrequent, is associated with significantly worse cavity LR and OS. Based on these results, a randomized trial of preoperative versus postoperative SRS is being designed.
术前立体定向放射外科治疗(SRS)是术后SRS的一种可行替代方案,可能降低放射性坏死(RN)和软脑膜疾病(LMD)复发的风险。本研究的目的是报告在一个扩大的患者队列中,相对于既往报告随访期更长的术前SRS的疗效和毒性。
回顾性分析接受术前SRS和计划切除治疗的脑转移瘤患者的病历。排除具有典型放射敏感性肿瘤、计划辅助全脑放疗或术后至少1个月未进行头颅影像学检查的患者。术前SRS剂量基于病变大小,较标准剂量降低约10-20%。手术一般在48小时内进行。
研究队列包括117例患者,共125个病灶接受了单次术前SRS和计划切除。117例患者中,24例纳入初始前瞻性试验;其余93例为连续治疗患者,进行回顾性分析。大多数患者有单个脑转移瘤(70.1%);42.7%为非小细胞肺癌,18.8%为乳腺癌,15.4%为黑色素瘤,11.1%为肾细胞癌。95.2%的病灶实现了大体全切。从SRS到手术的中位时间为2天,SRS中位剂量为15 Gy,中位肿瘤总体积为8.3 cm³。2年时的事件累积发生率如下:空洞局部复发(LR)为25.1%;远处脑转移为60.2%;LMD为4.3%;有症状的RN为4.8%。中位总生存期(OS)和2年OS率分别为17.2个月和36.7%。在多变量分析中,次全切除(STR,n = 6)与空洞LR风险增加(风险比[HR] 6.67,p = 0.008)和OS恶化(HR 2.63,p = 0.05)显著相关。
这项扩大和更新的分析证实,单次术前SRS可实现出色的空洞局部控制,RN或LMD风险极低。与术后SRS相比,术前SRS有几个潜在优势,包括由于照射体积较小且无需扩大空洞边缘而降低RN风险,以及由于术前手术时肿瘤细胞被灭活而降低LMD风险。次全切除虽不常见,但与明显更差的空洞LR和OS相关。基于这些结果,正在设计一项术前与术后SRS的随机试验。